Vestronidase alfa

Drug Profile

Vestronidase alfa

Alternative Names: Recombinant beta-glucuronidase - Ultragenyx; Recombinant human beta glucuronidase; rhGUS; UX-003

Latest Information Update: 25 May 2017

Price : $50

At a glance

  • Originator Saint Louis University
  • Developer Ultragenyx Pharmaceutical
  • Class Glucuronidases
  • Mechanism of Action Glucuronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis VII
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Mucopolysaccharidosis VII

Most Recent Events

  • 25 May 2017 Planned Prescription Drug User Fee Act (PDUFA) date for Mucopolysaccharidosis VII (In children, In adults, In adolescents) in USA (IV) is 2017-11-16
  • 23 May 2017 Preregistration for Mucopolysaccharidosis VII (In adolescents, In children, In adults) in European Union (IV)
  • 23 May 2017 Preregistration for Mucopolysaccharidosis VII (In children, In adults, In adolescents) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top